Albany Molecular says Bristol-Myers stops development of depression drug
(Reuters) - Albany Molecular Research Inc said partner Bristol-Myers Squibb Co would stop developing their experimental depression therapy.
Albany's shares tumbled 19 percent to $10.24 in afternoon trading.
Albany said Bristol-Myers stopped two mid-stage studies of the drug after it failed to show superiority over two other antidepressants. (link.reuters.com/fax32v)
Albany said the decision would not have an impact on its forecasts for the third quarter and 2013.
(Reporting by Pallavi Ail in Bangalore; Editing by Saumyadeb Chakrabarty)
- Israel keeps up Gaza assault; diplomats seek ceasefire |
- Rebels likely downed Malaysian jet 'by mistake': U.S. officials
- With sales sputtering, Apple's iPad looks to IBM alliance
- Islamic State crushes and coerces on march towards Baghdad
- UPDATE 4-Train carrying MH17 bodies reaches government-held Ukrainian city
Robert Blendon of the Harvard School of Public Health says the Affordable Care Act's unpopularity in 12 key states will keep it a central issue in the 2014 elections. Video